Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AngioDynamics, Inc. - Common Stock (NQ: ANGO )

12.94 +3.54 (+37.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AngioDynamics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance
AngioDynamics reported a Q4 2024 adjusted EPS loss of $(0.05), beating the consensus of $(0.16). Sales rose 1.9% to $79.1 million, driven by strong performance in the Med Tech segment. The company... 
Via Benzinga
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
ANGO Stock Earnings: AngioDynamics Beats EPS, Beats Revenue for Q4 2024
ANGO stock results show that AngioDynamics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2024. 
Via InvestorPlace
AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
From AngioDynamics, Inc.
Via Business Wire
Insiders Buying Zumiez And 3 Other Stocks
Although U.S. stocks closed little changed on Monday, there were a few notable insider trades. 
Via Benzinga
Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars
FDA grants 510(k) clearance to AngioDynamics' AlphaVac F1885 System for pulmonary embolism. Expanded indication broadens treatment options. Sales slightly below consensus, but pro forma basis sees... 
Via Benzinga
Exposures Product Safety
ANGO Stock Earnings: AngioDynamics Misses EPS, Misses Revenue for Q3 2024
ANGO stock results show that AngioDynamics missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning! 
Via InvestorPlace
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
From AngioDynamics, Inc.
Via Business Wire
Earnings Scheduled For April 4, 2024
Companies Reporting Before The Bell • Conagra Brands (NYSE:CAG) is likely to report quarterly earnings at $0.65 per share on revenue of $3.01 billion. 
Via Benzinga
AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement
AngioDynamics resolves decade-long patent litigation with Becton, Dickinson in landmark settlement, streamlining legal expenses and marking a significant milestone for the company. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference
From AngioDynamics, Inc.
Via Business Wire
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
While red ink signals danger, for these oversold stocks ready for rebound, they could imply upside opportunities. 
Via InvestorPlace
AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics (ANGO) Stock Sinks As Market Gains: Here's Why
The medical device maker's shares have seen an increase of 1.49% over the last month, not keeping up with the Medical sector's gain of 2.05% and the S&P 500's gain of 5.07%. 
Via Talk Markets
Topics Stocks
Exposures US Equities
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
From AngioDynamics, Inc.
Via Business Wire
Raymond James Maintains Outperform Rating for AngioDynamics: Here's What You Need To Know
Via Benzinga
Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why AngioDynamics Stock Got Destroyed Today
The medical technology company is a perennial underperformer, but its latest quarterly report was worse than expected. 
Via The Motley Fool
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Applied Therapeutics, Inc. 
Via Benzinga
ANGO Stock Earnings: AngioDynamics Beats EPS, Misses Revenue for Q2 2024
ANGO stock results show that AngioDynamics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Why Is Medical Devices-Focused AngioDynamics Stock Trading Lower Today?
AngioDynamics Inc (NASDAQ: ANGO) has reported a second-quarter (Q2) FY24 adjusted EPS loss of $(0.05), compared to the consensus of $(0.07) and EPS income of 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.